Global Leading Market Research Publisher QYResearch announces the release of its latest report "Moderate to Severe Atopic Dermatitis Treatment Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Moderate to Severe Atopic Dermatitis Treatment Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Moderate to Severe Atopic Dermatitis Treatment Drugs was estimated to be worth US 15,500millionin2025andisprojectedtoreachUS28,000 million by 2032, growing at a CAGR of 8.8% from 2026 to 2032. For dermatologists, immunologists, and pharmaceutical brand managers, the core business imperative lies in developing and prescribing moderate to severe atopic dermatitis (AD) treatment drugs that address the critical need for controlling severe itching (pruritus), erythema, skin lesions (papules, vesicles, excoriation, lichenification), sleep disturbance, and quality of life impairment in patients who are inadequately controlled with topical therapies (corticosteroids, calcineurin inhibitors, moisturizers). Driving factors: disease severity (moderate to severe AD significantly impacts daily life and mental health (anxiety, depression)), patient demand (symptom improvement, quality of life), technological progress (biologics targeting IL-4/IL-13 pathway, JAK (Janus kinase) inhibitors), market competition (Sanofi, Regeneron, Pfizer, Eli Lilly, LEO Pharma, AbbVie), and policy support (FDA breakthrough therapy, expedited approval, NMPA (National Medical Products Administration) priority review). Drug categories: biologics (injectable monoclonal antibodies: dupilumab (Dupixent, IL-4Rα antagonist), tralokinumab (Adbry, Adtralza, IL-13 antagonist), lebrikizumab (IL-13 antagonist), nemolizumab (IL-31Rα antagonist for pruritus)), oral JAK inhibitors (upadacitinib (Rinvoq, JAK1 selective), abrocitinib (Cibinqo, JAK1 selective), baricitinib (Olumiant, JAK1/2), ritlecitinib, tofacitinib), and other oral systemic agents (cyclosporine, methotrexate, azathioprine, mycophenolate mofetil). Types: injection (subcutaneous (SC), intravenous (IV)) and oral (tablets). Applications: child (pediatric AD, ages 6 months-12 years, 12-17 years) and adult (age 18+). Key players: Pfizer (US), LEO Pharma (Denmark), Sanofi (France), Eli Lilly (US). (Note: Regeneron (dupilumab, co-developed with Sanofi) not listed; AbbVie (rinvoq) not listed). 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/releases/5975535/moderate-to-severe-atopic-dermatitis-treatment-drugs The Moderate to Severe Atopic Dermatitis Treatment Drugs market is segmented as below: Pfizer LEO Pharma Sanofi Eli Lilly Segment by Type Injection Oral Segment by Application Child Adult 1. Market Drivers: Dupilumab (Dupixent) Blockbuster, JAK Inhibitor Approvals, and Unmet Need Several powerful forces are driving the moderate to severe AD treatment drugs market: Dupilumab (Dupixent) first biologic for AD (2017) – IL-4/IL-13 inhibition. Approved for adults, adolescents, children (6 months+). Sales >US$10B (2024). Global standard of care. Oral JAK inhibitors (upadacitinib (Rinvoq), abrocitinib (Cibinqo)) approved (2021-2022) – Rapid itch relief (2-7 days), convenient oral dosing. Head-to-head superiority vs dupilumab (upadacitinib). Boxed warning (JAK inhibitors: serious infections, malignancy, thrombosis, major adverse cardiovascular events (MACE)). Pediatric expansion (dupilumab, upadacitinib) – Infants (6 months - 5 years), children (6-11 years), adolescents (12-17 years). Long-term safety. Recent market data (December 2025): According to Global Info Research analysis, injection (biologics dupilumab, tralokinumab) dominates with approximately 65% revenue share (efficacy, safety, long-term). Oral JAK inhibitors 35% share (convenience, rapid onset). Adult (18+) largest application (70% share). Child (0-17 years) 30% share (fastest-growing 10-12% CAGR). North America (US) largest market (45% share). Europe 30% share. Asia-Pacific (Japan, China) 20% share. Sanofi (dupilumab), Pfizer (abrocitinib, ritlecitinib), Eli Lilly (lebrikizumab), LEO Pharma (tralokinumab, delgocitinib), AbbVie (upadacitinib) (not all listed). 2. Drug Types and Mechanisms Type Drug (Brand) Mechanism Route Dosing Key Efficacy (IGA 0/1) Share Biologic (injection) Dupilumab (Dupixent) IL-4Rα antagonist (blocks IL-4/IL-13) SC Q2W 36-38% ~55% Biologic (injection) Tralokinumab (Adbry) IL-13 antagonist SC Q2W 25% ~10% JAK Inhibitor (oral) Upadacitinib (Rinvoq) JAK1 selective Oral QD 45-50% ~20% JAK Inhibitor (oral) Abrocitinib (Cibinqo) JAK1 selective Oral QD 40-45% ~10% Key trials: SOLO 1/2 (dupilumab), ECZTRA 1/2/3 (tralokinumab), ADvocate 1/2 (lebrikizumab), Measure Up 1/2 (upadacitinib), JADE MONO-1/2 (abrocitinib). EASI (Eczema Area and Severity Index) 75. IGA (Investigator Global Assessment) 0/1 (clear/almost clear). Peak Pruritus NRS (Numerical Rating Scale) improvement. Safety: conjunctivitis (dupilumab), acne (upadacitinib), nausea (abrocitinib), herpes zoster, MACE, VTE (venous thromboembolism) (JAK). Exclusive observation (Global Info Research analysis): Moderate to severe AD treatment market has evolved from topical steroids to systemic immunomodulators (cyclosporine, methotrexate) to biologics (dupilumab) to oral JAK inhibitors (upadacitinib, abrocitinib). Dupilumab (Dupixent) standard of care. Upadacitinib (Rinvoq) superior efficacy (skin clearance, itch reduction) but boxed warning (JAK). Tralokinumab (Adbry) and lebrikizumab (Ebglyss, Lilly) IL-13 inhibitors. Nemolizumab (Mitsubishi Tanabe, Galderma) anti-IL-31 (pruritus). Pediatric approvals (6 months). Biosimilars expected dupilumab (2027-2029). User case – adult moderate to severe AD (December 2025): US patient (35 yo), EASI >20, IGA 3. Failed topical steroids. Initiate dupilumab (loading dose 600mg, then 300mg Q2W). Itch improves 2 weeks, skin clearance 16 weeks. Continue maintenance. User case – JAK inhibitor (January 2026): Adolescent (15 yo) with moderate to severe AD, prefers oral medication (no injection). Prescribed upadacitinib (15mg QD). Rapid itch relief (7 days), EASI-75 (16 weeks). Monitor CBC (complete blood count), LFT (liver function test), lipids. 3. Key Challenges Dupilumab ocular adverse events (conjunctivitis, blepharitis) – 10-20% incidence. Manage with eye drops, antihistamines. JAK inhibitor black box warning (serious infections, malignancy, thrombosis, MACE) – Regulatory restrictions (monitor CBC, lipids, cancer screening). Limited to patients failing biologics (label). Higher risk elderly, smokers, cardiovascular history. Technical difficulty – cost (US$30-50k per year): Biologics and JAK inhibitors expensive. Insurance prior authorization, step therapy. Technical development (October 2025): LEO Pharma (Denmark) announced tralokinumab pediatric approval (6-11 years). Label extension. 4. Competitive Landscape Key players include: Pfizer (US – abrocitinib (Cibinqo), ritlecitinib), LEO Pharma (Denmark – tralokinumab (Adbry)), Sanofi (France – dupilumab (Dupixent)), Eli Lilly (US – lebrikizumab, upadacitinib (Rinvoq) not co-developed?). Regeneron (dupilumab co-developer) not listed. AbbVie (upadacitinib) not listed. Sanofi, Pfizer, Eli Lilly leaders. Regional dynamics: North America (dupilumab dominant). Europe (dupilumab, tralokinumab). Asia-Pacific (Japan, China JAK inhibitors). 5. Outlook Moderate to severe atopic dermatitis treatment drugs market will grow at 8.8% CAGR to US$28.0 billion by 2032, driven by dupilumab dominance, JAK inhibitors (upadacitinib, abrocitinib), pediatric approvals, and oral convenience. Technology trends: IL-13 inhibitors, IL-31 inhibitors (pruritus), OX40/OX40L inhibitors (rocatinlimab, amlitelimab), and topical JAK inhibitors (ruxolitinib cream, delgocitinib). Asia-Pacific growth (10-12% CAGR). Biologics > JAK. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp